查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1552658

神经再生治疗市场 - 全球产业分析、规模、份额、成长、趋势和预测，2024-2034 年

Neuroregeneration Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 146 Pages | 商品交期: 2-10个工作天内

价格

神经再生治疗市场 - 报告范围

TMR 关于全球神经再生治疗市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。年期间，考虑2024年为基准年，2034年为预测年。报告中也提供了2024年至2034年全球神经再生治疗市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解神经再生治疗市场。

市场概况
2023年市场价值 370 亿美元
2034 年市场价值 648 亿美元
复合年增长率 5.3%

该报告深入探讨了全球神经再生治疗市场的竞争格局。全球神经再生治疗市场的主要参与者已经确定，并且每一位参与者都已根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球神经再生治疗市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概述

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：按药物类型

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依药物类型，2020-2034
    • N-甲基-D-天门冬胺酸受体拮抗剂
    • 胆碱酯酶抑制剂
    • 多巴胺激动剂
    • 免疫调节药物
    • 其他的
  • 市场吸引力：按药物类型

第 7 章：全球市场分析与预测：依指标类型

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依指标类型，2020-2034
    • 帕金森氏症
    • 阿兹海默症
    • 多发性硬化症
    • 亨丁顿舞蹈症
    • 其他的
  • 市场吸引力：依指示类型

第 8 章：全球市场分析与预测：依给药途径

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依给药途径，2020-2034年
    • 口服
    • 注射用
    • 透皮
  • 市场吸引力：依给药途径分类

第 9 章：全球市场分析与预测：按最终用户

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2020-2034
    • 医院药房
    • 零售药局
    • 网路药局
  • 市场吸引力：按最终用户划分

第 10 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按地区

第 11 章：北美市场分析与预测

第 12 章：欧洲市场分析与预测

第 13 章：亚太市场分析与预测

第 14 章：拉丁美洲市场分析与预测

第 15 章：中东和非洲市场分析与预测

第16章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • Biogen
    • Merck & Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Orion Corporation
    • UCB
    • Acadia Pharmaceuticals Inc.
    • Mitsubishi Chemical Group Corporation
    • H. Lundbeck A/S
    • Denali Therapeutics
    • Aquinnah Pharmaceuticals
    • Prevail Therapeutics
    • AZTherapies, Inc.
Product Code: TMRGL86322

Neuroregeneration Therapy Market - Scope of Report

TMR's report on the global neuroregeneration therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global neuroregeneration therapy market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global neuroregeneration therapy market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the neuroregeneration therapy market.

Market Snapshot
Market Value in 2023US$ 37 Bn
Market Value in 2034US$ 64.8 Bn
CAGR5.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global neuroregeneration therapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global neuroregeneration therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global neuroregeneration therapy market.

The report delves into the competitive landscape of the global neuroregeneration therapy market. Key players operating in the global neuroregeneration therapy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global neuroregeneration therapy market profiled in this report.

Key Questions Answered in Global neuroregeneration therapy Market Report:

  • What is the sales/revenue generated by neuroregeneration therapy across all regions during the forecast period?
  • What are the opportunities in the global neuroregeneration therapy market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Neuroregeneration Therapy Market - Research Objectives and Research Approach

The comprehensive report on the global neuroregeneration therapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global neuroregeneration therapy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global neuroregeneration therapy market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neuroregeneration Therapy Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Neuroregeneration Therapy Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Neuroregeneration Therapy Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2020-2034
    • 6.3.1. N-methyl-D-asparate Receptor Antagonists
    • 6.3.2. Cholinesterase Inhibitors
    • 6.3.3. Dopamine Agonists
    • 6.3.4. Immunomodulatory Drugs
    • 6.3.5. Others
  • 6.4. Market Attractiveness, by Drug Type

7. Global Neuroregeneration Therapy Market Analysis and Forecast, by Indication Type

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Indication Type, 2020-2034
    • 7.3.1. Parkinson's Disease
    • 7.3.2. Alzheimer's Disease
    • 7.3.3. Multiple Sclerosis
    • 7.3.4. Huntington Disease
    • 7.3.5. Others
  • 7.4. Market Attractiveness, by Indication Type

8. Global Neuroregeneration Therapy Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Transdermal
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Neuroregeneration Therapy Market Analysis and Forecast, by End-user

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2020-2034
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness, by End-user

10. Global Neuroregeneration Therapy Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Neuroregeneration Therapy Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Type, 2020-2034
    • 11.2.1. N-methyl-D-asparate Receptor Antagonists
    • 11.2.2. Cholinesterase Inhibitors
    • 11.2.3. Dopamine Agonists
    • 11.2.4. Immunomodulatory Drugs
    • 11.2.5. Others
  • 11.3. Market Attractiveness, by Drug Type
  • 11.4. Market Value Forecast, by Indication Type, 2020-2034
    • 11.4.1. Parkinson's Disease
    • 11.4.2. Alzheimer's Disease
    • 11.4.3. Multiple Sclerosis
    • 11.4.4. Huntington Disease
    • 11.4.5. Others
  • 11.5. Market Attractiveness, by Indication Type
  • 11.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.6.1. Oral
    • 11.6.2. Parenteral
    • 11.6.3. Transdermal
  • 11.7. Market Attractiveness, by Route of Administration
  • 11.8. Market Value Forecast, by End-user, 2020-2034
    • 11.8.1. Hospital Pharmacies
    • 11.8.2. Retail Pharmacies
    • 11.8.3. Online Pharmacies
  • 11.9. Market Attractiveness, by End-user
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Drug Type
    • 11.11.2. By Indication Type
    • 11.11.3. By Route of Administration
    • 11.11.4. By End-user
    • 11.11.5. By Country

12. Europe Neuroregeneration Therapy Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Type, 2020-2034
    • 12.2.1. N-methyl-D-asparate Receptor Antagonists
    • 12.2.2. Cholinesterase Inhibitors
    • 12.2.3. Dopamine Agonists
    • 12.2.4. Immunomodulatory Drugs
    • 12.2.5. Others
  • 12.3. Market Attractiveness, by Drug Type
  • 12.4. Market Value Forecast, by Indication Type, 2020-2034
    • 12.4.1. Parkinson's Disease
    • 12.4.2. Alzheimer's Disease
    • 12.4.3. Multiple Sclerosis
    • 12.4.4. Huntington Disease
    • 12.4.5. Others
  • 12.5. Market Attractiveness, by Indication Type
  • 12.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.6.1. Oral
    • 12.6.2. Parenteral
    • 12.6.3. Transdermal
  • 12.7. Market Attractiveness, by Route of Administration
  • 12.8. Market Value Forecast, by End-user, 2020-2034
    • 12.8.1. Hospital Pharmacies
    • 12.8.2. Retail Pharmacies
    • 12.8.3. Online Pharmacies
  • 12.9. Market Attractiveness, by End-user
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Drug Type
    • 12.11.2. By Indication Type
    • 12.11.3. By Route of Administration
    • 12.11.4. By End-user
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Neuroregeneration Therapy Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Type, 2020-2034
    • 13.2.1. N-methyl-D-asparate Receptor Antagonists
    • 13.2.2. Cholinesterase Inhibitors
    • 13.2.3. Dopamine Agonists
    • 13.2.4. Immunomodulatory Drugs
    • 13.2.5. Others
  • 13.3. Market Attractiveness, by Drug Type
  • 13.4. Market Value Forecast, by Indication Type, 2020-2034
    • 13.4.1. Parkinson's Disease
    • 13.4.2. Alzheimer's Disease
    • 13.4.3. Multiple Sclerosis
    • 13.4.4. Huntington Disease
    • 13.4.5. Others
  • 13.5. Market Attractiveness, by Indication Type
  • 13.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.6.1. Oral
    • 13.6.2. Parenteral
    • 13.6.3. Transdermal
  • 13.7. Market Attractiveness, by Route of Administration
  • 13.8. Market Value Forecast, by End-user, 2020-2034
    • 13.8.1. Hospital Pharmacies
    • 13.8.2. Retail Pharmacies
    • 13.8.3. Online Pharmacies
  • 13.9. Market Attractiveness, by End-user
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Drug Type
    • 13.11.2. By Indication Type
    • 13.11.3. By Route of Administration
    • 13.11.4. By End-user
    • 13.11.5. By Country/Sub-region

14. Latin America Neuroregeneration Therapy Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Type, 2020-2034
    • 14.2.1. N-methyl-D-asparate Receptor Antagonists
    • 14.2.2. Cholinesterase Inhibitors
    • 14.2.3. Dopamine Agonists
    • 14.2.4. Immunomodulatory Drugs
    • 14.2.5. Others
  • 14.3. Market Attractiveness, by Drug Type
  • 14.4. Market Value Forecast, by Indication Type, 2020-2034
    • 14.4.1. Parkinson's Disease
    • 14.4.2. Alzheimer's Disease
    • 14.4.3. Multiple Sclerosis
    • 14.4.4. Huntington Disease
    • 14.4.5. Others
  • 14.5. Market Attractiveness, by Indication Type
  • 14.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.6.1. Oral
    • 14.6.2. Parenteral
    • 14.6.3. Transdermal
  • 14.7. Market Attractiveness, by Route of Administration
  • 14.8. Market Value Forecast, by End-user, 2020-2034
    • 14.8.1. Hospital Pharmacies
    • 14.8.2. Retail Pharmacies
    • 14.8.3. Online Pharmacies
  • 14.9. Market Attractiveness, by End-user
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Drug Type
    • 14.11.2. By Indication Type
    • 14.11.3. By Route of Administration
    • 14.11.4. By End-user
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Neuroregeneration Therapy Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Type, 2020-2034
    • 15.2.1. N-methyl-D-asparate Receptor Antagonists
    • 15.2.2. Cholinesterase Inhibitors
    • 15.2.3. Dopamine Agonists
    • 15.2.4. Immunomodulatory Drugs
    • 15.2.5. Others
  • 15.3. Market Attractiveness, by Drug Type
  • 15.4. Market Value Forecast, by Indication Type, 2020-2034
    • 15.4.1. Parkinson's Disease
    • 15.4.2. Alzheimer's Disease
    • 15.4.3. Multiple Sclerosis
    • 15.4.4. Huntington Disease
    • 15.4.5. Others
  • 15.5. Market Attractiveness, by Indication Type
  • 15.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.6.1. Oral
    • 15.6.2. Parenteral
    • 15.6.3. Transdermal
  • 15.7. Market Attractiveness, by Route of Administration
  • 15.8. Market Value Forecast, by End-user, 2020-2034
    • 15.8.1. Hospital Pharmacies
    • 15.8.2. Retail Pharmacies
    • 15.8.3. Online Pharmacies
  • 15.9. Market Attractiveness, by End-user
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Drug Type
    • 15.11.2. By Indication Type
    • 15.11.3. By Route of Administration
    • 15.11.4. By End-user
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Biogen
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Merck & Co., Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Novartis AG
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Teva Pharmaceutical Industries Ltd.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Orion Corporation
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. UCB
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Acadia Pharmaceuticals Inc.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Mitsubishi Chemical Group Corporation
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. H. Lundbeck A/S
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Denali Therapeutics
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Aquinnah Pharmaceuticals
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Prevail Therapeutics
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. Financial Overview
      • 16.3.12.4. SWOT Analysis
      • 16.3.12.5. Strategic Overview
    • 16.3.13. AZTherapies, Inc.
      • 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.13.2. Product Portfolio
      • 16.3.13.3. Financial Overview
      • 16.3.13.4. SWOT Analysis
      • 16.3.13.5. Strategic Overview

List of Tables

  • Table 1: Global Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 2: Global Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 3: Global Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 4: Global Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 5: Global Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 6: North America Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 7: North America Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 8: North America Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 9: North America Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 10: North America Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 11: Europe Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 13: Europe Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 14: Europe Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 15: Europe Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 16: Asia Pacific Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 18: Asia Pacific Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 19: Asia Pacific Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Asia Pacific Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 21: Latin America Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 23: Latin America Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 24: Latin America Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 25: Latin America Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 26: Middle East & Africa Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 28: Middle East & Africa Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 29: Middle East & Africa Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Middle East & Africa Neuroregeneration Therapy Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 1: Global Neuroregeneration Therapy Market Size (US$ Bn), by Region, 2023 and 2034
  • Figure 2: Global Neuroregeneration Therapy Market Revenue (US$ Bn), by Drug Type, 2023
  • Figure 3: Global Neuroregeneration Therapy Market Value Share, by Drug Type, 2023
  • Figure 4: Global Neuroregeneration Therapy Market Revenue (US$ Bn), by Indication Type, 2023
  • Figure 5: Global Neuroregeneration Therapy Market Value Share, by Indication Type, 2023
  • Figure 6: Global Neuroregeneration Therapy Market Revenue (US$ Bn), by Route of Administration, 2023
  • Figure 7: Global Neuroregeneration Therapy Market Value Share, by Route of Administration, 2023
  • Figure 8: Global Neuroregeneration Therapy Market Revenue (US$ Bn), by End-user, 2023
  • Figure 9: Global Neuroregeneration Therapy Market Value Share, by End-user, 2023
  • Figure 10: Global Neuroregeneration Therapy Market Value Share, by Region, 2023
  • Figure 11: Global Neuroregeneration Therapy Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 12: Global Neuroregeneration Therapy Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 13: Global Neuroregeneration Therapy Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 14: Global Neuroregeneration Therapy Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 15: Global Neuroregeneration Therapy Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 16: Global Neuroregeneration Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 17: Global Neuroregeneration Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 18: Global Neuroregeneration Therapy Market Revenue (US$ Bn), by End-user, 2023
  • Figure 19: Global Neuroregeneration Therapy Market Value Share, by End-user, 2023
  • Figure 20: Global Neuroregeneration Therapy Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Neuroregeneration Therapy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Neuroregeneration Therapy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Neuroregeneration Therapy Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Neuroregeneration Therapy Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Neuroregeneration Therapy Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 26: North America Neuroregeneration Therapy Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 27: North America Neuroregeneration Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 28: North America Neuroregeneration Therapy Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 29: North America Neuroregeneration Therapy Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 30: North America Neuroregeneration Therapy Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 31: North America Neuroregeneration Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 32: North America Neuroregeneration Therapy Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 33: Europe Neuroregeneration Therapy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Neuroregeneration Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Neuroregeneration Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Neuroregeneration Therapy Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 37: Europe Neuroregeneration Therapy Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 38: Europe Neuroregeneration Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 39: Europe Neuroregeneration Therapy Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 40: Europe Neuroregeneration Therapy Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 41: Europe Neuroregeneration Therapy Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 42: Europe Neuroregeneration Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 43: Europe Neuroregeneration Therapy Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 44: Asia Pacific Neuroregeneration Therapy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Neuroregeneration Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Neuroregeneration Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Neuroregeneration Therapy Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 48: Asia Pacific Neuroregeneration Therapy Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 49: Asia Pacific Neuroregeneration Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Asia Pacific Neuroregeneration Therapy Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Asia Pacific Neuroregeneration Therapy Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 52: Asia Pacific Neuroregeneration Therapy Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 53: Asia Pacific Neuroregeneration Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 54: Asia Pacific Neuroregeneration Therapy Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 55: Latin America Neuroregeneration Therapy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Neuroregeneration Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Neuroregeneration Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Neuroregeneration Therapy Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 59: Latin America Neuroregeneration Therapy Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 60: Latin America Neuroregeneration Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 61: Latin America Neuroregeneration Therapy Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 62: Latin America Neuroregeneration Therapy Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 63: Latin America Neuroregeneration Therapy Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 64: Latin America Neuroregeneration Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 65: Latin America Neuroregeneration Therapy Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 66: Middle East & Africa Neuroregeneration Therapy Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Neuroregeneration Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Neuroregeneration Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Neuroregeneration Therapy Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 70: Middle East & Africa Neuroregeneration Therapy Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 71: Middle East & Africa Neuroregeneration Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 72: Middle East & Africa Neuroregeneration Therapy Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 73: Middle East & Africa Neuroregeneration Therapy Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 74: Middle East & Africa Neuroregeneration Therapy Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 75: Middle East & Africa Neuroregeneration Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 76: Middle East & Africa Neuroregeneration Therapy Market Attractiveness Analysis, by End-user, 2024-2034